title: Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: Z R
authors: ZR
authors: Chalmers
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: S M
authors: SM
authors: Ali
authors: Department of Pathology, Stanford School of Medicine, Stanford, CA, USA.
authors: R S
authors: RS
authors: Ohgami
authors: 1] Foundation Medicine Inc., Cambridge, MA, USA [2] Clinical Laboratory, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
authors: P V
authors: PV
authors: Campregher
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: G M
authors: GM
authors: Frampton
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: R
authors: R
authors: Yelensky
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: J A
authors: JA
authors: Elvin
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: N A
authors: NA
authors: Palma
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: R
authors: R
authors: Erlich
authors: Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
authors: J-A
authors: JA
authors: Vergilio
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: J
authors: J
authors: Chmielecki
authors: 1] Foundation Medicine Inc., Cambridge, MA, USA [2] Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
authors: J S
authors: JS
authors: Ross
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: P J
authors: PJ
authors: Stephens
authors: Northwest Georgia Oncology Centers, Jasper Cancer Center, Jasper, GA, USA.
authors: R
authors: R
authors: Hermann
authors: Foundation Medicine Inc., Cambridge, MA, USA.
authors: V A
authors: VA
authors: Miller
authors: Northwest Georgia Oncology Centers, Jasper Cancer Center, Jasper, GA, USA.
authors: C R
authors: CR
authors: Miles
mesh_terms: D001549:Benzamides / Q000008:administration & dosage; D004802:Eosinophilia / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D005260:Female; D015894:Genome, Human; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D000068877:Imatinib Mesylate; D007938:Leukemia; D008875:Middle Aged; D009196:Myeloproliferative Disorders; D015514:Oncogene Proteins, Fusion / Q000235:genetics* / Q000302:isolation & purification; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D038501:Tankyrases / Q000235:genetics*
chemical_list: D001549:Benzamides; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C437334:TNKS2 protein, human; D038501:Tankyrases; D020796:Receptor, Platelet-Derived Growth Factor alpha